The Dow Chemical Company - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
The Dow Chemical Company

Pharmaceutical Technology

Corporate description



Dow is a diversified chemical company that harnesses the power of science and technology to improve living daily. The company offers a range of innovative products and services to customers in more than 175 countries, helping them to provide everything from fresh water, food, and pharmaceuticals to paints, packaging, and personal care products. Built on a commitment to its principles of sustainability, Dow has annual sales of $46 billion and employs 42,000 people worldwide. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted.

Technical services

Dow offers a range of services in excipient technology, chemical manufacturing, and formulation technology capabilities for intermediates, active compounds, stabilizers, and functional ingredients.



Dow's emerging excipient technologies include foamed binder granulation, melt extrusion and melt coating, oral film delivery, and excipient polymers for hard-shell capsules. Conventional excipient technologies include aqueous-and solvent-based controlled release, granulation, tablet coating, liquid systems, mucosal bioadhesives, suppositories, and many others. Visit http://www.dowexcipients.com/.

Dowpharma Contract Manufacturing Services manufactures small-molecule APIs and intermediates, catalysts, CGMP polymers, oligonucleotides, and poly(ethylene) glycols (PEGs) and provides microbial fermentation technology (Pseudomonas-based "Pfenex Expression Technology") for protein expression. Dowpharma draws upon 30+ years of relevant CGMP compliance and can provide client support in regulatory filing and validation strategies. Visit http://www.dowpharma.com/.

Additional Dow capabilities include expertise in hydrogen cyanide chemistry, nitroparaffin chemistry, and radiopharmaceutical technologies.

Facilities

Dow operates more than 230 manufacturing facilities in 38 countries, including five CGMP API and intermediate and biologics production and research facilities in the United States and Europe.

Major products

  • excipients, including "METHOCEL" and "ETHOCEL" cellulose ethers, "POLYOX" water-soluble Resins NF, and "CARBOWAX" "SENTRY" polyethylene glycols;
  • functional emulsifiers, humectants, and viscosifiers, including alkanolamines, ethanolamines, "OPTIM" Glycerin, NF-grade polyethylene glycols, and polyacrylates;
  • chelating agents, including "VERSENE" chelating agents and specialty chelants;
  • advanced intermediates and active pharmaceutical ingredients available through pharmaceutical services, including HCN and nitroparaffin derivatives.

Markets served

Dow offers technologies, services, and ingredient materials appropriate for branded ethical pharmaceuticals, generic drugs, over-the-counter pharmaceuticals, vitamins, and supplements.

The Dow Chemical Company

PO Box 1206
Midland, MI 48642-1206

TELEPHONE
800.447.4369
989.832.1560

FAX
989.832.1465

WEB SITE
http://www.dow.com/

NUMBER OF EMPLOYEES
42,000

Date Founded
1897

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
39%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here